Sarepta Therapeutics, Inc.
US ˙ NasdaqGS ˙ US8036071004

SecuritySRPT / Sarepta Therapeutics, Inc.
InstitutionFox Run Management, L.l.c.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Fox Run Management, L.l.c. closes position in SRPT / Sarepta Therapeutics, Inc.

On November 12, 2025 - Fox Run Management, L.l.c. filed a 13F-HR form disclosing ownership of 0 shares of Sarepta Therapeutics, Inc. (US:SRPT) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 6, 2025 disclosing 27,706 shares of Sarepta Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-12 2025-09-30 13F SAREPTA THERAPEUTICS COM 803607100 0 -27,706 -100.00 0 -100.00
2025-08-06 2025-06-30 13F SAREPTA THERAPEUTICS COM 803607100 27,706 27,706 474 0.0789
2024-08-13 2024-06-30 13F SAREPTA THERAPEUTICS COM 803607100 0 -6,801 -100.00 0 -100.00
2024-05-13 2024-03-31 13F SAREPTA THERAPEUTICS COM 803607100 6,801 -2,732 -28.66 880 -4.24 0.1898
2024-02-13 2023-12-31 13F SAREPTA THERAPEUTICS COM 803607100 9,533 9,533 919 0.2345
2022-11-07 2022-09-30 13F SAREPTA THERAPEUTICS COM 803607100 0 -7,626 -100.00 0 -100.00
2022-08-12 2022-06-30 13F SAREPTA THERAPEUTICS COM 803607100 7,626 341 4.68 572 0.53 0.2856
2022-05-10 2022-03-31 13F SAREPTA THERAPEUTICS COM 803607100 7,285 7,285 569 0.3168
2021-08-05 2021-06-30 13F SAREPTA THERAPEUTICS COM 803607100 0 -4,902 -100.00 0 -100.00
2021-05-17 2021-03-31 13F SAREPTA THERAPEUTICS COM 803607100 4,902 2,916 146.83 365 54.01 0.6582
2019-10-17 2019-03-31 13F SAREPTA THERAPEUTICS COM 803607100 1,986 1,986 237 0.1339
2019-01-15 2018-12-31 13F SAREPTA THERAPEUTICS COM 803607100 0 -3,117 -100.00 0 -100.00
2018-10-05 2018-09-30 13F SAREPTA THERAPEUTICS COM 803607100 3,117 3,117 503 0.2193
2018-01-18 2017-12-31 13F SAREPTA THERAPEUTICS COM 803607100 0 -4,500 -100.00 0 -100.00
2017-10-23 2017-09-30 13F SAREPTA THERAPEUTICS COM 803607100 4,500 4,500 204 0.0578
2017-07-10 2017-06-30 13F SAREPTA THERAPEUTICS COM 803607100 0 -13,100 -100.00 0 -100.00
2017-04-17 2017-03-31 13F SAREPTA THERAPEUTICS COM 803607100 13,100 13,100 388 0.1583
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.